Zevra Therapeutics Inc’s recent filing unveils that its Director Shih Alvin acquired Company’s shares for reported $0.16 million on Sep 12 ’25. In the deal valued at $7.89 per share,20,000 shares were bought. As a result of this transaction, Shih Alvin now holds 20,000 shares worth roughly $0.14 million.
Then, Bode John B bought 5,000 shares, generating $45,825 in total proceeds. Upon buying the shares at $9.16, the Director now owns 45,000 shares.
Before that, Thompson Rahsaan sold 24,000 shares. Zevra Therapeutics Inc shares valued at $221,004 were divested by the Chief Legal & Compliance at a price of $9.21 per share. As a result of the transaction, Thompson Rahsaan now holds 42,666 shares, worth roughly $0.31 million.
H.C. Wainwright initiated its Zevra Therapeutics Inc [ZVRA] rating to a Buy in a research note published on July 02, 2025; the price target was $26. Guggenheim began covering ZVRA with “Buy” recommendation on October 07, 2024. Maxim Group maintained its rating on September 24, 2024. It rated ZVRA as “a Buy”.
Price Performance Review of ZVRA
On Monday, Zevra Therapeutics Inc [NASDAQ:ZVRA] saw its stock fall -6.71% to $7.23. Over the last five days, the stock has lost -13.21%. Zevra Therapeutics Inc shares have fallen nearly -2.17% since the year began. Nevertheless, the stocks have fallen -13.31% over the past one year.
How much short interest is there in Zevra Therapeutics Inc?
A steep rise in short interest was recorded in Zevra Therapeutics Inc stocks on 2025-08-29, growing by 2.25 million shares to a total of 6.89 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 4.64 million shares. There was a rise of 32.68%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 24, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $17 price target.
